Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is
the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over …

Purpose: Trastuzumab induced cardiotoxicity (TIC) was defined as the most serious side
effect. Long term cardiac effects of trastuzumab are still not known, thus we aimed to …

Background The ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular
velocity (e′, E/e′ ratio) as estimated by tissue Doppler imaging is a noninvasive surrogate …

Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term
Trastuzumab Treatment - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

Background. Adjuvant trastuzumab is a highly effective targeted treatment that improves
survival for patients with HER2-positive breast cancer. However, trastuzumab interruption is …

Purpose Asymptomatic decline in left ventricular ejection fraction (LVEF) or heart failure (HF)
occurs in up to 25% of patients treated with trastuzumab and can result in incomplete breast …

Background Adjuvant trastuzumab therapy increases survival rates in patients with early
HER2-positive breast cancer, although it can be potentially cardiotoxic. The aim of this study …

Background. Cardiotoxicity is an important adverse effect of adjuvant breast cancer
treatment with trastuzumab and three monthly left ventricular ejection fraction (LVEF) …

Breast cancer is the leading cause of cancer death in women worldwide. Trastuzumab, the
main HER2-targeted treatment, faces limitations due to potential cardiotoxicity. The …

Introduction Trastuzumab has led to a significant improvement in the treatment of both
advanced and early breast cancer that over-expresses HER2 receptors. However, it is …